Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Ps...or cumulatively across multiple stocks, these tiny trades , presumably generated by some sort AI trading bot, could be returning decent profit with little risk??? Still a pain in the rear, and should be banned!!!
No idea, but the sp will rise sharply on decent buying volume and I assume the tiny trades are generated by some sort of Trading Bot, a pain in the backside as far as I'm concerned, but I've witnessed these tiny trades on other stocks recently, and maybe some sort of trial before whoever is behind them, decides to increase the value from tiny to worthwhile????
Something similar for Genflow, highly likely. Gla :-)
Rejuveron lands $75m to advance healthy aging portfolio; expands focus in Middle East
2 HOURS AGO
Longevity biotech opens strategic Abu Dhabi office as Mubadala Capital joins Series B investment round.
Longevity biotech company Rejuveron Life Sciences has successfully closed a dual-tranche Series B equity and convertible loan financing round, raising a total of $75 million.
The funding was co-led by Catalio Capital Management and Apeiron Investment Group, the family office and private investment firm of entrepreneur Christian Angermayer.
The round was also joined by new investor Mubadala Capital, a subsidiary of Mubadala Investment Company, the $280 billion sovereign investor group headquartered in Abu Dhabi, UAE.
htTps://longevity.technology/news/rejuveron-lands-75m-to-advance-healthy-aging-portfolio-expands-focus-in-middle-east/amp/
A compelling watch. Gla :-)
WHAT TOP Scientists Say About SIRT6: The KEY to LONGEVITY??
9.9K views · 2 months ago
htTps://youtu.be/3F6l2ZZIgJo?si=m8-yf7g1gNYbn_6G
Exciting times ahead on several fronts, and the FDA has recently given approval for another longevity clinical trial for dogs, and so all bodes well for Genflow. Gl :-)
New tricks: Loyal’s companion dog longevity study receives FDA protocol concurrence.
Loyal, a clinical-stage veterinary medicine company developing drugs intended to extend the healthspan and lifespan of dogs, has announced it has received protocol concurrence from the FDA for its companion dog longevity study.
Longevity.Technology: Loyal is on a mission is to help dogs everywhere live longer, healthier lives – and that means taking on the development of the first FDA-approved drugs explicitly intended to extend lifespan and healthspan. On the path to FDA approval, Loyal must run a clinical trial that objectively and robustly demonstrates that its drug extends dogs’ healthy lifespan – and does so safely. However, no-one has developed a dog – or human – longevity drug before, so Loyal is building the path to FDA approval largely from scratch.
Today, Loyal has announced that last week it learned from the FDA that the company has received protocol concurrence for its companion dog longevity study. This is good news for the longevity biotech sector, especially welcome as it comes on the same day that tech lender Silicon Valley Bank collapsed and was put under the control of the US Federal Deposit Insurance Corporation – news that left biotechs and VCs reeling.
Loyal’s protocol concurrence means the FDA has reviewed the scientific design of its study and determined that it meets their high quality standards, and will validate whether Loyal’s drug does indeed extend canine lifespan and healthspan.
In a nutshell, this means that if Loyal’s study demonstrates that its dog longevity drug extends healthy lifespan, those results will be sufficient to support bringing the drug to market for dogs across the US.
“Our concurrence means we fundamentally agree with your proposed design, execution, and analyses…” – FDA Center for Veterinary Medicine
https://longevity.technology/news/first-longevity-clinical-study-design-fetches-fda-approval/amp/
Wow!!! A great find Poerter, a mega multi-bag in a blink. Gl :-)
First in human proof-of-concept Phase I/ II Trial in Werner Syndrome
Genflow Biosciences is on the fast track to become a top performing biotechnology longevity powerhouse. An aggressive clinical development plan is underway. A team of seasoned industry leaders leads with confidence knowing there is short-term milestone potential.
Leveraging major unmet needs within communities affected by issues related to ageing is a key factor for aligning with Genflow Biosciences.
First in human proof-of-concept phase I/II trial in Non-Alcoholic Steato Hepatitis (NASH) and Werner Syndrome in patients that will be conducted in Sardinia. We will apply to Orphan drug designation for this indication. Werner syndrome is a heritable human premature ageing disease. As a classical premature ageing disease, etiological exploration of WS can shed light on the mechanisms of normal human ageing and facilitate the development of interventional strategies to improve health span.
First in human proof-of-concept Phase I/ II Trial in NASH
NASH is a liver disease that affect an estimated 35 million people globally with an increasing prevalence. NASH is becoming one of the leading causes of chronic liver disease and liver transplant and remains a significant unmet medical need with no approved therapies. The adipogenesis, anti-fibrotic and anti-tumoral effects discovered in our recent pre-clinical program make GF-1002 a promising candidate for the treatment of NASH. The choice of NASH as potential indication for GF-1002 allows Genflow to benefit of clear regulatory accelerated development pathway and a potential conditional fast track approval.
0 0
Lots of potential positive material newsflow in the pipeline to add significant value, expected soon. Gla :-)
The potential to extend healthy lifespan with groundbreaking science
The SIRT6 gene is recognized as a master regulator of healthy ageing. SIRT6 overexpression has been shown to lead to a healthy lifespan extension in both male and female mice. Genflow Biosciences intends to promote healthy ageing by providing extra copies of a variant of the Human SIRT6 gene found in centenarians. Genflow Biosciences is developing an ethical, safe and efficient gene delivery system to deliver this centenarian variant of SIRT6 gene.
THE PRODUCTS PIPELINE
Our Lead Compound GF-1002
A 120-minute infusion of AAV vectors allows a safe transient episomal expression of extra copies of a centenarian variant of the SIRT6 gene without integration into the DNA, without risk of self-replication, without transfer of bacterial genetic material, without immunogenic or mutagenesis concerns.
Pre Clinical Stage GF-1002
GF-1002 is a suspension of an AAV vector-based gene therapy for intravenous infusion and intends to improve DNA maintenance by delivering extra copies of the Centenarian Variant. The AAV gene therapy works by modifying (or ‘recombining’) a natural AAV to produce a safe and efficient vector to deliver a transgene into cells. The transgene is the ’gene of interest’ (“GOI”) to be provided to the cells. In the case of GF-1002, the GOI is the coding sequence of the Centenarian Variant.
Pre Clinical Stage GF-4001
GF-4001 is a non-Human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs).
Pre Clinical Stage GF-3001
GF-3001 is an formulation of andeno-associated viral vector-based gene therapy. It is a recombinant AAV with fibroblast tropism containing a transgene encoding the cDNA portion of a variant of the human SIRT6 gene found in centenarians for delivery to the dermal fibroblast.
‘Elixir of life’ on the horizon thanks to longevity gene in naked mole rats
SEPTEMBER 6 2023
ROCHESTER, N.Y. — The naked mole rat is bringing modern medicine one step closer to creating the “elixir of life.” Researchers have successfully transferred a longevity gene from the species into a mouse. This groundbreaking procedure has potential implications for promoting longer, healthier lives in humans.
The naked mole rat, despite its less-than-appealing appearance, boasts a remarkable lifespan and a significant resistance to age-related diseases. Researchers from the University of Rochester in New York are optimistic about the insights this provides into the mysteries of aging and potential lifespan extension for society.
For context, naked mole rats are mouse-sized rodents that live up to 41 years, nearly 10 times the lifespan of rodents of comparable size. Distinctly, they show little to no signs of neurodegeneration, cardiovascular disease, arthritis, or cancer as they age. In this research, a gene from the mole rat was introduced into mice, leading to enhanced health and increased longevity in the mice.
“Our study provides a proof of principle that unique longevity mechanisms that evolved in long-lived mammalian species can be exported to improve the lifespans of other mammals,” says Vera Gorbunova, the Doris Johns Cherry Professor of biology and medicine at Rochester, in a university release.
very interesting if he's in the us, hopefully approval from the belguim regulatory authorities, and now a meeting with the fda . gla :-)
outlook
our key objectives for 2023 are:
• first interaction with european health regulatory authorities ema/famhp/***g mid 2023.
to be followed by meeting with the fda.
• continuing the constitution of the investigational medicinal product dossier (impd).
• broadening our scientific collaborations with top-tier longevity research institutions.
• exploiting new patent and other ip opportunities.
Fingers crossed Eric has a very BIG positive UPdate to deliver very soon. Gla :-)
A Look at Longevity Industry: Interview with Dr. Eric Leire, CEO of Genflow Biosciences
Andrii: Recently, I read a book by Dr. David Sinclair, “Lifespan: Why We Age―and Why We Don't Have To,” and I found his "information theory of aging" quite interesting. What do you think about it?
Eric: I also adored the book that David Sinclair, a distinguished academic in the field of aging, wrote. The book was released in 2019, and it is incredible to see how far aging research has come in just four years. In his book, Sinclair reveals a bold new theory for why we age, suggesting that the aging hallmarks are symptoms of epigenetic changes. He explains that aging is a disease and that disease is treatable. I completely agree with his theory. At Genflow, we also believe that aging is plastic and that we can reverse it.
htTps://www.biopharmatrend.com/post/623-interview-dr-eric-leire-ceo-of-genflow-biosciences/
Interesting enough, much of David Sinclair’s research, who is singled out above, is focused on Sirt6.!!!!??? Gla holders...here's hoping Genflow are one of the companies highlighted in doing " really compelling things right now"!!!??? News this month to add significant value, highly likely regardless. :-)
David Sinclair
@davidasinclair
Turning up the fruit fly Sirt6 gene slows aging and extends lifespan, just as in and possibly , apparently by mimicking fasting and slowing protein production
htTp://pnas.org/content/119/5/e2111176119… http://pubmed.ncbi.nlm.nih.gov/34050173/
‘We’re at the longevity inflection point – and the explosion is coming.’
It’s not long to go, now, before the Longevity Investors Conference kicks off in Switerland. One of the speakers on Day 2 of next month’s event is Dr Greg Bailey, the Executive Chairman of Juvenescence who will be presenting on Biotech Investment Opportunities.’
To me, being able to invest right now into antiaging and modifying longevity, is exactly at the inflection point that being given the opportunity to invest in generated AI was at three or four years ago – I think it’s gonna have that sort of explosion. We’re seeing it with some of David Sinclair’s work, we’re going to see some astonishing things out of Altos and BioAge. There’s a number of companies that are doing really compelling things right now that are going to explode the space. And I’m not comparing us with the end game – I think generated AI has enormous societal changes and economics associated with it, but just as far as the trajectory of the curve for next two or three years, this, to me, is the time to invest.
hTtps://longevity.technology/news/were-at-the-longevity-inflection-point-and-the-explosion-is-coming/amp/
Tick UP coming!!! Gla ;-)
I bought in last Friday and have enjoyed a significant rise on my investment, whilst you and your desperate band of cohorts have detered other pi's from doing the same...i think you need to apologise to those who you have discouraged, although no doubt your real motives are due o your short position on your spread bet...ho ho ....Gla holders.......always best to make your own investment decisions. ;-)
Beware of people who incessently and repetitively discourage and deter investors, petroinvestor and his desperate deramping cohorts are responsible for many pi's missing out on a 50% plus plus rise since last Friday's low. Gla holders ;-)
75p a share, very solid and encouraging, and adds a tad more liquidity with so few shares in free float. Gl ;-)
Still very much under the radar, but perfectly poised for significant upside from this bargain low sp, as positive newsflow is deleivered during H2 2023 for full investor focus and market interest, both here and the US...... Gla Holders :-)
Murray Galbraith, Chief Executive Officer of YouneeqAI said:
"We are incredibly excited to close this transaction with the RC365 team. RC365's current business model, customers, future plans and goals align perfectly with YouneeqAI's platform. Our platform, product offerings and related IP are constantly improving and evolving, expanding reach and possibilities for customers. With over several decades of combined AI and technical services experience, we look forward to a long, prosperous and mutually beneficial partnership with RC365."
Issue of Equity
Application for the initial 3,000,000 new Ordinary Shares to be admitted to the Official List of the UK Listing Authority and to trading on the Main Market of the London Stock Exchange has been made. Dealings are expected to commence on or around 6 September 2023. All new Ordinary Shares were issued at 75p per share.
Conditional on Admission of the 3,000,000 new Ordinary Shares, the Company's issued ordinary share capital will be 128,534,591 Ordinary Shares, which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.